{"ticker": {"uuid": "5bbe8403-426f-4260-af71-1b220387af33", "symbol": "ENTX", "name": "Entera Bio Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?", "summary": "Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion, highlighting the significant value placed on oral therapies for conditions traditionally treated by injections. Entera Bio is positioned to follow a similar path with its lead asset, EB613, an ora", "url": "https://www.tradingview.com/news/financewire:9e2f76e0b094b:0-after-crinetics-10-billion-deal-could-entera-bio-be-the-next-category-defining-oral-peptide-story/", "source_name": "TradingView", "published_at": "2026-07-15T13:13:41", "published_display": "15 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Entera Bio Ltd. \u2013 NASDAQ:ENTX", "summary": "This article displays the \"Price to earnings forward\" value for Entera Bio Ltd. (NASDAQ: ENTX) as part of its financial overview on the TradingView platform. The information is presented without specific numerical data, indicating that the market was closed with no trades when th", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:11", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Entera Bio Ltd. \u2013 FWB:5DT", "summary": "This page from TradingView provides financial information for Entera Bio Ltd. (FWB:5DT), specifically focusing on its price-to-earnings forward metric. The content includes an overview of the company's financials, news, community insights, forecasts, and seasonal data, noting tha", "url": "https://www.tradingview.com/symbols/FWB-5DT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:11:19", "published_display": "27 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entera Bio Ltd. \u2013 FWB:5DT", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" value for Entera Bio Ltd. (FWB:5DT) on the Frankfurt Stock Exchange. It indicates that the market was closed at the time of viewing and no trades were recorded, while also listing various financial data source", "url": "https://www.tradingview.com/symbols/FWB-5DT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:11", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "This page from TradingView provides financial information for Entera Bio Ltd. under the stock symbol A2JQXP on the Lang & Schwarz Exchange. It specifically highlights the enterprise value to EBIT forward metric for the company. The content appears to be a stub or a section of a l", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:18", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "The article focuses on the \"Price to book forward\" metric for Entera Bio Ltd. (LSX:A2JQXP), indicating a financial data point for the company. It appears to be a stub or a data point from a financial platform like TradingView, with no further detailed analysis provided.", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:38:58", "published_display": "26 Jun 2026 18:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd. Actuals & Estimates (HAM:5DT)", "summary": "This article provides an overview of Entera Bio Ltd. (HAM:5DT) stock, including financial actuals and analyst estimates. It details the stock's future price forecast with a max and min estimate of 7.68 EUR, its historical highest and lowest prices, and key financial figures such ", "url": "https://www.tradingview.com/symbols/HAM-5DT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:18", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Entera Bio Ltd. (ENTX) stock, including a 1-year price target of $9.00 from one analyst. It details ENTX's recent price performance, market capitalization, earnings reports, and other financial metrics. The piece also addresses frequently aske", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:18", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "This article provides financial information for Entera Bio Ltd. (LSX:A2JQXP) on TradingView, specifically focusing on its Price to Sales (forward) metric. It mentions the company's listing on the Lang & Schwarz Exchange under the Health Technology/Pharmaceuticals: Major sector. T", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:24", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis", "summary": "Entera Bio Ltd. announced positive feedback from the FDA on its 12-month registrational Phase 3 study protocol for EB613, an oral anabolic tablet for postmenopausal women with osteoporosis. The FDA approved plans for a single randomized, double-blind, placebo-controlled trial wit", "url": "https://finance.yahoo.com/healthcare/articles/entera-bio-receives-positive-fda-123000553.html", "source_name": "Market source", "published_at": "2026-06-26T00:12:31", "published_display": "26 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2JQXP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Entera Bio Ltd. (A2JQXP) stock for 2027, based on analyst opinions. It includes current stock price, market capitalization, volatility, and historical performance, alongside recent financial data like earnings and revenue. The", "url": "https://www.tradingview.com/symbols/LS-A2JQXP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:13", "published_display": "25 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9", "summary": "H.C. Wainwright has reiterated its Buy rating for Entera Bio (ENTX.US) and maintained its target price at $9. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71961532/hc-wainwright-maintains-entera-bio-entxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T11:42:21", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback", "summary": "H.C. Wainwright has reiterated a Buy rating and a $9.00 price target for Entera Bio (NASDAQ:ENTX) after the FDA accepted its Phase 3 registrational protocol for EB613, an oral osteoporosis treatment. Despite the stock surge following the announcement, an InvestingPro analysis ind", "url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-entera-bio-stock-rating-on-fda-feedback-93CH-4757908?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T11:40:11", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Stock On Track For Best Day In Over 5 Years \u2014 What\u2019s Driving The Rally?", "summary": "Entera Bio Ltd. (ENTX) shares surged over 52% after receiving positive feedback from the FDA regarding the design of its late-stage clinical trial for EB613, an experimental once-daily pill for postmenopausal osteoporosis. The FDA's backing for a single, large registrational tria", "url": "https://stocktwits.com/news-articles/markets/equity/entx-stock-on-track-for-best-day-in-over-5-years-whats-driving-rally/cZKM5L5R79E", "source_name": "Stocktwits", "published_at": "2026-06-23T09:10:25", "published_display": "23 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline", "summary": "Entera Bio Ltd. (ENTX) stock has seen a nearly 10% increase following positive clinical trial news showcased at ENDO 2026. The company presented strong preclinical data for EB612 and EB618, targeting hypoparathyroidism and obesity respectively, alongside Phase 1 data for its oral", "url": "https://www.timothysykes.com/news/entera-bio-ltd-entx-news-2026_06_22/", "source_name": "Timothy Sykes", "published_at": "2026-06-22T23:09:40", "published_display": "22 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs Entera Bio\u2019s 750-patient osteoporosis trial for EB613", "summary": "Entera Bio received positive feedback from the FDA for its investigational drug EB613, an oral anabolic tablet designed for postmenopausal osteoporosis. The FDA approved a single 750-patient Phase 3 trial, with total hip BMD at 12 months as the primary endpoint, to support a New ", "url": "https://www.stocktitan.net/news/ENTX/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-68x1kod67lj7.html", "source_name": "Stock Titan", "published_at": "2026-06-22T14:40:57", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/entera-bio-advances-oral-osteoporosis-130357924.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:03:57+00:00", "published_display": "22 Jun 2026 13:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For", "summary": "Entera Bio received positive FDA feedback on the Phase 3 protocol for EB613, its oral PTH(1-34) tablet for postmenopausal osteoporosis. This significantly de-risks the development pathway for EB613, which aims to be the first oral anabolic treatment for osteoporosis, a market cur", "url": "https://www.tradingview.com/news/financewire:211d7e0a1094b:0-with-positive-fda-feedback-on-phase-3-entera-bio-just-got-the-answer-the-market-was-waiting-for/", "source_name": "TradingView", "published_at": "2026-06-22T13:09:40", "published_display": "22 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Entera Bio Ltd (ENTX), including its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:24", "published_display": "18 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a brief overview of Entera Bio Ltd (ENTX) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:09:40", "published_display": "18 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Entera Bio Ltd (ENTX), noting its current valuation score of 6.71, which ranks it 300 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.58 and mentions that relevant data for P/B,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:09:40", "published_display": "18 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Entera Bio Ltd (ENTX) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $10.00 for ENTX, with one analyst giving it a \"Buy\" rating. The company's previous quarter's EPS was -$0.06, outperforming the market expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:32", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio reports preclinical data for two oral peptide programs By Investing.com", "summary": "Entera Bio Ltd. (NASDAQ:ENTX) presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs, co-developed with OPKO Health Inc., utilize Entera's N-Tab oral peptide platfo", "url": "https://m.za.investing.com/news/stock-market-news/entera-bio-reports-preclinical-data-for-two-oral-peptide-programs-93CH-4330643?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T07:40:30", "published_display": "17 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026", "summary": "Entera Bio Ltd. announced robust preclinical data for its oral peptide programs, EB612 and EB618, at ENDO 2026. EB612, an oral long-acting PTH(1-34) for hypoparathyroidism, demonstrated strong bioavailability and sustained calcium increases in preclinical models, with an IND fili", "url": "https://www.sahmcapital.com/news/content/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth1-34-for-hypoparathyroidism-and-eb618-oral-glp-1glucagon-for-obesity-at-endo-2026-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T19:40:57", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio reports preclinical data for two oral peptide programs", "summary": "Entera Bio Ltd. presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs utilize the company's N-Tab oral peptide platform technology and are co-developed with OPKO H", "url": "https://m.uk.investing.com/news/stock-market-news/entera-bio-reports-preclinical-data-for-two-oral-peptide-programs-93CH-4730657?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-16T18:09:40", "published_display": "16 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental oral hormone pills aim at hypoparathyroidism, obesity", "summary": "Entera Bio (NASDAQ: ENTX) presented robust preclinical data for its oral drug candidates EB612 and EB618 at ENDO 2026. EB612, for hypoparathyroidism, demonstrated sustained calcium restoration in preclinical models, with an IND filing targeted for late 2026. EB618, for obesity an", "url": "https://www.stocktitan.net/news/ENTX/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth-1-34-49gcufbcr5eb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:10:01", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPaDNmLWVYZVJPNlBIMlhWeTY5eGRzbXdVOEdUbW1CN3BLdWd1T0FjSmR4RXdVVnVUSldtcVRaWUwwWHpPLUZsU1M2RnRRZS1VSHVPN3p0N25TT3dxTHpLNXdiZ01wb1FtcE9FRjdIdjVRR1Y1NlNBVHY4V1cwc2EyNnh1OFZSYnJrd2F3c1FWZ3RfempDNjhYckZvb2hfb1lrTVl4UDRxdXU5YVJoeTVyOWIyMGJ5S3FOUWhvUlpWOER4cGlp?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX SEC Filings - Entera Bio Ltd 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan.net provides comprehensive access to Entera Bio Ltd. (ENTX) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors monitoring the Nasdaq-listed clinical-stage biopharmaceutical company. The filings cover financial results, regulatory updat", "url": "https://www.stocktitan.net/sec-filings/ENTX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T07:10:00", "published_display": "16 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera\u2019s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/endo-2026-oral-presentation-highlights-124500939.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:45:00+00:00", "published_display": "15 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daily oral tablet EB613 shows comparable results to Forteo", "summary": "Entera Bio presented Phase 1 data at ENDO 2026 for its single-tablet oral EB613, showing comparable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, calcemic effects, and safety to multi-tablet EB613 and injectable Forteo. This data supports advancing the single-tablet for", "url": "https://www.stocktitan.net/news/ENTX/endo-2026-oral-presentation-highlights-comparative-clinical-data-for-yhyiqfmm5wg8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:40:52", "published_display": "15 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera\u2019s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entera-eb613-first-class-oral-125000980.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:50:00+00:00", "published_display": "28 May 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Entera Bio Ltd. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOOENBSWpORThobWtMYWpFaHA4clQ3aUJ0NkZILWlsdy1ONThPU0FQLVI1RmlxXzU0dWlOWjJiVjdDY3ZDTlZYaWtheGJDUk9VbXpsZ0x2RnBFVENPTmEyT1M0S1piMW01MzgwbHNudG1BeGE0MWk2M1QtXzQ4QmZsNzU2Q3RERWJhaF9fcm9SUm9BdmY3UjR1eHdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entera-announces-first-quarter-2026-200500448.html", "source_name": "GlobeNewswire", "published_at": "2026-05-08T20:05:00+00:00", "published_display": "08 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera pushes an osteoporosis pill toward Phase 3 as cash hits $20.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNX3FXWmluSFo0djRYMlgyYnBndDAzajI1S2tJRTFXazRyWldWX2xjMW5JZlk4X21JQ1VNUHRzdk11Njh3ekhmREFCNzRuNzR6aUJpbGItaG1Dbi0yckZ5VktVcy1VTFlIWDZ3WTM3SjVNbmsycF81WkRqUVg3UGlNcldlRW14YmlYZXNvQ2g0ZXJneUNLN1hQaVhaLW5PYUlZRFRjR09VYmVsUktSblQ0UEhJVzVhU2dIc193bQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/entera-bio-entx-upgraded-buy-160005095.html", "source_name": "Zacks", "published_at": "2026-04-29T16:00:05+00:00", "published_display": "29 Apr 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near", "summary": "", "url": "https://finance.yahoo.com/m/a43a5728-8bc5-3c0f-ad33-6db960df3140/entera-bio-touts-eb613-oral.html", "source_name": "MarketBeat", "published_at": "2026-04-24T23:33:00+00:00", "published_display": "24 Apr 2026 23:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/briefcast-publishes-transcript-entera-bios-155900416.html", "source_name": "GlobeNewswire", "published_at": "2026-04-20T15:59:00+00:00", "published_display": "20 Apr 2026 15:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Announces Pricing of $10.0 Million Direct", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxOb2JhT3huREVlb1FfMnV1Vm1KOVJXaUF0UHNoelFMV2g0VUxiRE9FU1lZeU94SFRNNGxNbUJOV2l2c3h5M3c2Y3hid3dEX2lYNEJMclM4MHZ5N1NBUzlTTVBPRXdPalpBUHg2SzJydkU5ZzI4R24xZUJLNVpweERtclJ2cG9oaW9IaUhMUlNLc0hiQ1gzU3lJRHAtaU9YS0lrelJkN0ludTUwcHVhd2ZoallnYmlsenhGR2FmdF9QOFB6aEZDaEwzZzFsUzlsM2lwWnBUUWRMTU85ZnptQ3B0enpEOHAydWp5V0JmUnY0U2ViYXJXSmJ1b0dKTnI0N0NLaE0yN3hQeURMQ3Z3VFgxTndZY2YyZDB2bHo0TUtVUWRkM0x3V0N4eXNpZ1QtVnM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWHQweUt3dDNFOWh4R0hvSHB5Z2lqaTNEMy12bGdPZkVWMlhtcGx1bXdTamFpZzZlOGJoUkd0Z2p1MFByc3JYQW8yOUxQQ0NNdVR2UXgtWC1uWnlRdUxqM01FZm5YamNvbWxEWGY1U1BCSXQxQnpFSWhfdE9XMmZJQkRQSkVfWkVoRkxldFVoX0xxWm54MGdTbWdGM1lZSm9WRF95S0w0UTljdUJDXzdIdGJQeWZLZ0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPVjRtOHpXSUZOeDd4TEt2bi1hSDNvODlWb2cwSFV3TjJfVUdwb3JuejJ4Ny1DQVhRcWhnUWJvVzRyMXRjbkpDLUVsX244SEh5YkREeFFmcGxBNE00WWVGejNwcGxRWG1wd2FEdXhWOHNsVTdUZEhuU3hmRjRCVXA5TkVDNWVtWjVqV0trb1Nra1lGZ2N2ZldHZWh1TDZlY3VxVC1qVDNINTQwQWdMbFlabnNIUF9iUFNnUlpCdmI1X1NFRThrMnFoRUx1VWExc2QwSzJoajV3cmlsQkg00gHiAUFVX3lxTFBWb3BxVzNCY0kwSTJSSjJIczdFZlpSUC16ZlpsRnJTdjlQLVk0TmVDZm9JMzVKTmRRekhGMVU0SHBHMGZRMkkwUVMxWGlMRERKbWhzSlY0T1I2YkNmMWpvaXI1clB4WGJyS29NOTRWNUJKX3EzWE43RWQ4WGRtQTRSTktISnVhUTJnNVFCWTZIeWR2SHUyWFEyS0cwUlE4Rnk4SHZjQ1lRUW1GQ0FSamF6YW9BNl9PNERGMVNDZUV6OFdGNzd0dFhkQXFqOGE5NUNjSkhUbXJzQ2JMUHJxWmtnS2c?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio (ENTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE05djNOTjFRUmc1Z2VMd2tvUU1lZ1ZySjM5RG52S21vWnZNX3dmcmxjWnlxQTI0YmVIbGtDc3JEcmh4aDd2Q1hTYnplc0pYUG9jTlhUb29CcG5JUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-07-10T19:13:05+00:00", "published_display": "10 Jul 2018 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?", "summary": "Vertex Pharmaceuticals recently acquired Crinetics Pharmaceuticals for $10 billion, highlighting the significant value placed on oral therapies for conditions traditionally treated by injections. Entera Bio is positioned to follow a similar path with its lead asset, EB613, an ora", "url": "https://www.tradingview.com/news/financewire:9e2f76e0b094b:0-after-crinetics-10-billion-deal-could-entera-bio-be-the-next-category-defining-oral-peptide-story/", "source_name": "TradingView", "published_at": "2026-07-15T13:13:41", "published_display": "15 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Entera Bio Ltd. \u2013 NASDAQ:ENTX", "summary": "This article displays the \"Price to earnings forward\" value for Entera Bio Ltd. (NASDAQ: ENTX) as part of its financial overview on the TradingView platform. The information is presented without specific numerical data, indicating that the market was closed with no trades when th", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:11", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Entera Bio Ltd. \u2013 FWB:5DT", "summary": "This page from TradingView provides financial information for Entera Bio Ltd. (FWB:5DT), specifically focusing on its price-to-earnings forward metric. The content includes an overview of the company's financials, news, community insights, forecasts, and seasonal data, noting tha", "url": "https://www.tradingview.com/symbols/FWB-5DT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:11:19", "published_display": "27 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entera Bio Ltd. \u2013 FWB:5DT", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" value for Entera Bio Ltd. (FWB:5DT) on the Frankfurt Stock Exchange. It indicates that the market was closed at the time of viewing and no trades were recorded, while also listing various financial data source", "url": "https://www.tradingview.com/symbols/FWB-5DT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:11", "published_display": "27 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "This page from TradingView provides financial information for Entera Bio Ltd. under the stock symbol A2JQXP on the Lang & Schwarz Exchange. It specifically highlights the enterprise value to EBIT forward metric for the company. The content appears to be a stub or a section of a l", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:18", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "The article focuses on the \"Price to book forward\" metric for Entera Bio Ltd. (LSX:A2JQXP), indicating a financial data point for the company. It appears to be a stub or a data point from a financial platform like TradingView, with no further detailed analysis provided.", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:38:58", "published_display": "26 Jun 2026 18:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd. Actuals & Estimates (HAM:5DT)", "summary": "This article provides an overview of Entera Bio Ltd. (HAM:5DT) stock, including financial actuals and analyst estimates. It details the stock's future price forecast with a max and min estimate of 7.68 EUR, its historical highest and lowest prices, and key financial figures such ", "url": "https://www.tradingview.com/symbols/HAM-5DT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:18", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Entera Bio Ltd. (ENTX) stock, including a 1-year price target of $9.00 from one analyst. It details ENTX's recent price performance, market capitalization, earnings reports, and other financial metrics. The piece also addresses frequently aske", "url": "https://www.tradingview.com/symbols/NASDAQ-ENTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:18", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Entera Bio Ltd. \u2013 LSX:A2JQXP", "summary": "This article provides financial information for Entera Bio Ltd. (LSX:A2JQXP) on TradingView, specifically focusing on its Price to Sales (forward) metric. It mentions the company's listing on the Lang & Schwarz Exchange under the Health Technology/Pharmaceuticals: Major sector. T", "url": "https://www.tradingview.com/symbols/LSX-A2JQXP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:24", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis", "summary": "Entera Bio Ltd. announced positive feedback from the FDA on its 12-month registrational Phase 3 study protocol for EB613, an oral anabolic tablet for postmenopausal women with osteoporosis. The FDA approved plans for a single randomized, double-blind, placebo-controlled trial wit", "url": "https://finance.yahoo.com/healthcare/articles/entera-bio-receives-positive-fda-123000553.html", "source_name": "Market source", "published_at": "2026-06-26T00:12:31", "published_display": "26 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2JQXP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Entera Bio Ltd. (A2JQXP) stock for 2027, based on analyst opinions. It includes current stock price, market capitalization, volatility, and historical performance, alongside recent financial data like earnings and revenue. The", "url": "https://www.tradingview.com/symbols/LS-A2JQXP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:10:13", "published_display": "25 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9", "summary": "H.C. Wainwright has reiterated its Buy rating for Entera Bio (ENTX.US) and maintained its target price at $9. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71961532/hc-wainwright-maintains-entera-bio-entxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T11:42:21", "published_display": "24 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback", "summary": "H.C. Wainwright has reiterated a Buy rating and a $9.00 price target for Entera Bio (NASDAQ:ENTX) after the FDA accepted its Phase 3 registrational protocol for EB613, an oral osteoporosis treatment. Despite the stock surge following the announcement, an InvestingPro analysis ind", "url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-entera-bio-stock-rating-on-fda-feedback-93CH-4757908?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T11:40:11", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Stock On Track For Best Day In Over 5 Years \u2014 What\u2019s Driving The Rally?", "summary": "Entera Bio Ltd. (ENTX) shares surged over 52% after receiving positive feedback from the FDA regarding the design of its late-stage clinical trial for EB613, an experimental once-daily pill for postmenopausal osteoporosis. The FDA's backing for a single, large registrational tria", "url": "https://stocktwits.com/news-articles/markets/equity/entx-stock-on-track-for-best-day-in-over-5-years-whats-driving-rally/cZKM5L5R79E", "source_name": "Stocktwits", "published_at": "2026-06-23T09:10:25", "published_display": "23 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline", "summary": "Entera Bio Ltd. (ENTX) stock has seen a nearly 10% increase following positive clinical trial news showcased at ENDO 2026. The company presented strong preclinical data for EB612 and EB618, targeting hypoparathyroidism and obesity respectively, alongside Phase 1 data for its oral", "url": "https://www.timothysykes.com/news/entera-bio-ltd-entx-news-2026_06_22/", "source_name": "Timothy Sykes", "published_at": "2026-06-22T23:09:40", "published_display": "22 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs Entera Bio\u2019s 750-patient osteoporosis trial for EB613", "summary": "Entera Bio received positive feedback from the FDA for its investigational drug EB613, an oral anabolic tablet designed for postmenopausal osteoporosis. The FDA approved a single 750-patient Phase 3 trial, with total hip BMD at 12 months as the primary endpoint, to support a New ", "url": "https://www.stocktitan.net/news/ENTX/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-68x1kod67lj7.html", "source_name": "Stock Titan", "published_at": "2026-06-22T14:40:57", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/entera-bio-advances-oral-osteoporosis-130357924.html", "source_name": "MT Newswires", "published_at": "2026-06-22T13:03:57+00:00", "published_display": "22 Jun 2026 13:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For", "summary": "Entera Bio received positive FDA feedback on the Phase 3 protocol for EB613, its oral PTH(1-34) tablet for postmenopausal osteoporosis. This significantly de-risks the development pathway for EB613, which aims to be the first oral anabolic treatment for osteoporosis, a market cur", "url": "https://www.tradingview.com/news/financewire:211d7e0a1094b:0-with-positive-fda-feedback-on-phase-3-entera-bio-just-got-the-answer-the-market-was-waiting-for/", "source_name": "TradingView", "published_at": "2026-06-22T13:09:40", "published_display": "22 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Entera Bio Ltd (ENTX), including its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant financial data for these categories has not yet been disclosed by the c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T18:39:24", "published_display": "18 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a brief overview of Entera Bio Ltd (ENTX) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:09:40", "published_display": "18 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Entera Bio Ltd (ENTX), noting its current valuation score of 6.71, which ranks it 300 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.58 and mentions that relevant data for P/B,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:09:40", "published_display": "18 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Entera Bio Ltd (ENTX) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $10.00 for ENTX, with one analyst giving it a \"Buy\" rating. The company's previous quarter's EPS was -$0.06, outperforming the market expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-entx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:32", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio reports preclinical data for two oral peptide programs By Investing.com", "summary": "Entera Bio Ltd. (NASDAQ:ENTX) presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs, co-developed with OPKO Health Inc., utilize Entera's N-Tab oral peptide platfo", "url": "https://m.za.investing.com/news/stock-market-news/entera-bio-reports-preclinical-data-for-two-oral-peptide-programs-93CH-4330643?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T07:40:30", "published_display": "17 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026", "summary": "Entera Bio Ltd. announced robust preclinical data for its oral peptide programs, EB612 and EB618, at ENDO 2026. EB612, an oral long-acting PTH(1-34) for hypoparathyroidism, demonstrated strong bioavailability and sustained calcium increases in preclinical models, with an IND fili", "url": "https://www.sahmcapital.com/news/content/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth1-34-for-hypoparathyroidism-and-eb618-oral-glp-1glucagon-for-obesity-at-endo-2026-2026-06-16", "source_name": "Sahm", "published_at": "2026-06-16T19:40:57", "published_display": "16 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio reports preclinical data for two oral peptide programs", "summary": "Entera Bio Ltd. presented positive preclinical data for two oral peptide programs, EB612 for hypoparathyroidism and EB618 for obesity and metabolic disorders, at ENDO 2026. Both programs utilize the company's N-Tab oral peptide platform technology and are co-developed with OPKO H", "url": "https://m.uk.investing.com/news/stock-market-news/entera-bio-reports-preclinical-data-for-two-oral-peptide-programs-93CH-4730657?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-16T18:09:40", "published_display": "16 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental oral hormone pills aim at hypoparathyroidism, obesity", "summary": "Entera Bio (NASDAQ: ENTX) presented robust preclinical data for its oral drug candidates EB612 and EB618 at ENDO 2026. EB612, for hypoparathyroidism, demonstrated sustained calcium restoration in preclinical models, with an IND filing targeted for late 2026. EB618, for obesity an", "url": "https://www.stocktitan.net/news/ENTX/entera-reports-robust-preclinical-data-for-eb612-oral-la-pth-1-34-49gcufbcr5eb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T12:10:01", "published_display": "16 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPaDNmLWVYZVJPNlBIMlhWeTY5eGRzbXdVOEdUbW1CN3BLdWd1T0FjSmR4RXdVVnVUSldtcVRaWUwwWHpPLUZsU1M2RnRRZS1VSHVPN3p0N25TT3dxTHpLNXdiZ01wb1FtcE9FRjdIdjVRR1Y1NlNBVHY4V1cwc2EyNnh1OFZSYnJrd2F3c1FWZ3RfempDNjhYckZvb2hfb1lrTVl4UDRxdXU5YVJoeTVyOWIyMGJ5S3FOUWhvUlpWOER4cGlp?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENTX SEC Filings - Entera Bio Ltd 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan.net provides comprehensive access to Entera Bio Ltd. (ENTX) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors monitoring the Nasdaq-listed clinical-stage biopharmaceutical company. The filings cover financial results, regulatory updat", "url": "https://www.stocktitan.net/sec-filings/ENTX/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T07:10:00", "published_display": "16 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera\u2019s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/endo-2026-oral-presentation-highlights-124500939.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:45:00+00:00", "published_display": "15 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daily oral tablet EB613 shows comparable results to Forteo", "summary": "Entera Bio presented Phase 1 data at ENDO 2026 for its single-tablet oral EB613, showing comparable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, calcemic effects, and safety to multi-tablet EB613 and injectable Forteo. This data supports advancing the single-tablet for", "url": "https://www.stocktitan.net/news/ENTX/endo-2026-oral-presentation-highlights-comparative-clinical-data-for-yhyiqfmm5wg8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T12:40:52", "published_display": "15 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera\u2019s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entera-eb613-first-class-oral-125000980.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:50:00+00:00", "published_display": "28 May 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Entera Bio Ltd. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOOENBSWpORThobWtMYWpFaHA4clQ3aUJ0NkZILWlsdy1ONThPU0FQLVI1RmlxXzU0dWlOWjJiVjdDY3ZDTlZYaWtheGJDUk9VbXpsZ0x2RnBFVENPTmEyT1M0S1piMW01MzgwbHNudG1BeGE0MWk2M1QtXzQ4QmZsNzU2Q3RERWJhaF9fcm9SUm9BdmY3UjR1eHdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/entera-announces-first-quarter-2026-200500448.html", "source_name": "GlobeNewswire", "published_at": "2026-05-08T20:05:00+00:00", "published_display": "08 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera pushes an osteoporosis pill toward Phase 3 as cash hits $20.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNX3FXWmluSFo0djRYMlgyYnBndDAzajI1S2tJRTFXazRyWldWX2xjMW5JZlk4X21JQ1VNUHRzdk11Njh3ekhmREFCNzRuNzR6aUJpbGItaG1Dbi0yckZ5VktVcy1VTFlIWDZ3WTM3SjVNbmsycF81WkRqUVg3UGlNcldlRW14YmlYZXNvQ2g0ZXJneUNLN1hQaVhaLW5PYUlZRFRjR09VYmVsUktSblQ0UEhJVzVhU2dIc193bQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/entera-bio-entx-upgraded-buy-160005095.html", "source_name": "Zacks", "published_at": "2026-04-29T16:00:05+00:00", "published_display": "29 Apr 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near", "summary": "", "url": "https://finance.yahoo.com/m/a43a5728-8bc5-3c0f-ad33-6db960df3140/entera-bio-touts-eb613-oral.html", "source_name": "MarketBeat", "published_at": "2026-04-24T23:33:00+00:00", "published_display": "24 Apr 2026 23:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/briefcast-publishes-transcript-entera-bios-155900416.html", "source_name": "GlobeNewswire", "published_at": "2026-04-20T15:59:00+00:00", "published_display": "20 Apr 2026 15:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio Announces Pricing of $10.0 Million Direct", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwJBVV95cUxOb2JhT3huREVlb1FfMnV1Vm1KOVJXaUF0UHNoelFMV2g0VUxiRE9FU1lZeU94SFRNNGxNbUJOV2l2c3h5M3c2Y3hid3dEX2lYNEJMclM4MHZ5N1NBUzlTTVBPRXdPalpBUHg2SzJydkU5ZzI4R24xZUJLNVpweERtclJ2cG9oaW9IaUhMUlNLc0hiQ1gzU3lJRHAtaU9YS0lrelJkN0ludTUwcHVhd2ZoallnYmlsenhGR2FmdF9QOFB6aEZDaEwzZzFsUzlsM2lwWnBUUWRMTU85ZnptQ3B0enpEOHAydWp5V0JmUnY0U2ViYXJXSmJ1b0dKTnI0N0NLaE0yN3hQeURMQ3Z3VFgxTndZY2YyZDB2bHo0TUtVUWRkM0x3V0N4eXNpZ1QtVnM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWHQweUt3dDNFOWh4R0hvSHB5Z2lqaTNEMy12bGdPZkVWMlhtcGx1bXdTamFpZzZlOGJoUkd0Z2p1MFByc3JYQW8yOUxQQ0NNdVR2UXgtWC1uWnlRdUxqM01FZm5YamNvbWxEWGY1U1BCSXQxQnpFSWhfdE9XMmZJQkRQSkVfWkVoRkxldFVoX0xxWm54MGdTbWdGM1lZSm9WRF95S0w0UTljdUJDXzdIdGJQeWZLZ0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-31T08:00:00+00:00", "published_display": "31 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entera Bio (ENTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE05djNOTjFRUmc1Z2VMd2tvUU1lZ1ZySjM5RG52S21vWnZNX3dmcmxjWnlxQTI0YmVIbGtDc3JEcmh4aDd2Q1hTYnplc0pYUG9jTlhUb29CcG5JUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-07-10T19:13:05+00:00", "published_display": "10 Jul 2018 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 49, "sentiment_summary": {"positive": 18, "negative": 1, "neutral": 30, "score": 59, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 1.66, "latest_week": "2026-07-10", "one_week_move": -0.3, "four_week_move": 34.6, "twelve_week_move": 29.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.091719, "market_dynamics_buy_signal": false, "relative_strength": -18.320408, "fair_value_gap": 1.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 42.6938, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.3% over one week, +34.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.3% over one week, +34.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?"}], "updated_at": "2026-07-16T00:46:26.545056+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}